Fosgonimeton
An investigational drug for neurodegenerative diseases
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Fosgonimeton is an investigational drug currently being studied for its potential use in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is designed to modulate the activity of the HGF/MET signaling pathway, which is believed to play a role in neuroprotection and neuroregeneration.
Mechanism of Action[edit | edit source]
Fosgonimeton acts by enhancing the activity of the hepatocyte growth factor (HGF) and its receptor, MET. The HGF/MET pathway is involved in various cellular processes, including cell growth, survival, and differentiation. In the context of neurodegenerative diseases, activation of this pathway is thought to promote neuronal survival and repair, potentially slowing disease progression.
Clinical Development[edit | edit source]
Fosgonimeton is currently in the clinical trial phase, with studies focusing on its safety, tolerability, and efficacy in patients with Alzheimer's disease. Early-phase trials have shown promising results, indicating that the drug is well-tolerated and may have beneficial effects on cognitive function.
Potential Benefits[edit | edit source]
The potential benefits of Fosgonimeton include:
- Neuroprotection: By activating the HGF/MET pathway, Fosgonimeton may protect neurons from degeneration.
- Neuroregeneration: The drug may promote the repair and regeneration of damaged neurons.
- Cognitive Improvement: Clinical trials are investigating whether Fosgonimeton can improve cognitive function in patients with Alzheimer's disease.
Challenges and Considerations[edit | edit source]
While Fosgonimeton shows promise, there are several challenges and considerations in its development:
- Long-term Safety: The long-term safety profile of Fosgonimeton needs to be established through extensive clinical trials.
- Efficacy: Demonstrating significant clinical efficacy in large-scale trials is crucial for regulatory approval.
- Mechanistic Understanding: Further research is needed to fully understand the mechanisms by which Fosgonimeton exerts its effects.
Also see[edit | edit source]
- Alzheimer's disease
- Parkinson's disease
- Neuroprotection
- Neuroregeneration
- Hepatocyte growth factor
- MET receptor
Template:Neuropharmacology footer
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
